FTSE 100 news / Companies and sectors / Pharma and healthcare / 9 October 2026
Pharma and healthcare: sector news on Friday 9 October 2026
Average tone +2.2 (slightly positive) across 5 companies with relevant coverage, from 44 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| GSK | +2.0 | 21 | Coverage was dominated by GSK's Viola Davis shingles campaign, plus positive news on ViiV's HIV trial and a blood-cancer acquisition. |
| AstraZeneca | +7.0 | 15 | Coverage was mostly positive, led by EU approvals for Trixeo in asthma and a camizestrant companion diagnostic, a China approval for a breast cancer drug, and a Jefferies Buy rating. |
| Smith & Nephew | +6.8 | 4 | Coverage centred on the European launch of the CARTIHEAL cartilage implant, which reads as a positive step for its sports medicine business. |
| Convatec | −2.2 | 2 | Coverage centred on a 1.54% share price fall alongside reported ostomy findings, and on whether new product launches can offset a reimbursement hit. |
| Haleon | −2.8 | 2 | Coverage centred on JPMorgan trimming its price target for Haleon, which leans negative. |
Strongest stories in the sector
- +10.0 GSK’s ViiV says long-acting HIV treatment meets key Phase IIIb endpoint
ViiV long-acting HIV treatment meets Phase IIIb endpoint - +9.2 AstraZeneca’s Trixeo approved in EU for asthma
EU approval of Trixeo for asthma widens its use - +9.2 Astrazeneca, Daiichi Sankyo's Breast Cancer Drug Approved in China
China approval of breast cancer drug with Daiichi Sankyo - +9.2 Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
EU companion diagnostic approval supports camizestrant launch in Europe - +9.2 Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
Product launch of CARTIHEAL across key European markets expands its offering - +8.3 Jefferies keeps Buy rating for AstraZeneca stock at GBp 17,500
Jefferies maintains Buy with high price target - +7.5 AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth?
FDA filing for new lung cancer treatment supports oncology growth - +7.0 Is Smith & Nephew plc (LSE:SN.) expanding its sports medicine reach with this week's European cartilage implant launch?
Frames European cartilage implant launch as sports medicine expansion - +6.7 AZN rallies as Summit Therapeutics investment completes
Shares rallied as Summit investment completed - +6.7 Can GSK plc (LSE:GSK) strengthen its blood-cancer pipeline after this week's T cell engager acquisition?
T cell engager acquisition strengthens blood-cancer pipeline - −6.7 GSK plc : Gets a Sell rating from JP Morgan
JP Morgan Sell rating - +5.8 AstraZeneca Executes $2B Summit Investment to Advance Bispecific ADC Cancer Combos
$2B Summit investment to advance bispecific ADC combinations
Pharma and healthcare: every day · FTSE 100 overview for the day